Megan K Young1, Shu-Kay Ng, George Mellick, Paul A Scuffham. 1. School of Medicine, Population and Social Health Research Group, GHI, Griffith University, Logan Campus, University Drive, Meadowbrook, QLD, 4131, Australia. megan.young@griffith.edu.au
Abstract
PURPOSE: The EuroQoL (EQ-5D) is ideal to compare quality of life across conditions. However, the Parkinson's Disease Questionnaire (PDQ-39) is often the only quality-of-life instrument used in Parkinson's disease research. We aimed to identify associations between PDQ-39 domains and EQ-5D domains, and compare different methods of developing a function to map the PDQ-39 to EQ-5D scores. METHODS: Adults with Parkinson's disease self-completed both instruments. Ordinal regression identified associations between PDQ-39 domain scores and each EQ-5D domain. Modeling (n = 80) and validation sets (n = 16) were randomly generated. Overall performance of four methods of mapping the PDQ-39 to EQ-5D scores (using PDQ-39 domains and total score in ordinal and linear regression) was assessed with the validation set, followed by assessing the equivalence of observed and predicted EQ-5D scores on the full dataset controlling for sociodemographic factors. RESULTS: Different sets of PDQ-39 domains were associated with each EQ-5D domain. For example, PDQ-39 "Activities of Daily Living" and "Social Support" were associated with EQ-5D "Personal Care," while PDQ-39 "Emotional Well-being" was associated with EQ-5D "Anxiety/Depression." Over one-third (37.5 %) of predictions from ordinal regressions had an error <0.01 % (compared to 6.3 % for linear regressions). The EQ-5D scores predicted with ordinal regression using PDQ-39 domains were similar in distribution and association with sociodemographic factors to the observed EQ-5D scores. CONCLUSIONS: Of the four methods tested, using PDQ-39 domains in ordinal regression was superior for mapping EQ-5D scores. The function reported here may prove particularly useful for cost-utility analyses comparing Parkinson's disease with other conditions.
PURPOSE: The EuroQoL (EQ-5D) is ideal to compare quality of life across conditions. However, the Parkinson's Disease Questionnaire (PDQ-39) is often the only quality-of-life instrument used in Parkinson's disease research. We aimed to identify associations between PDQ-39 domains and EQ-5D domains, and compare different methods of developing a function to map the PDQ-39 to EQ-5D scores. METHODS: Adults with Parkinson's disease self-completed both instruments. Ordinal regression identified associations between PDQ-39 domain scores and each EQ-5D domain. Modeling (n = 80) and validation sets (n = 16) were randomly generated. Overall performance of four methods of mapping the PDQ-39 to EQ-5D scores (using PDQ-39 domains and total score in ordinal and linear regression) was assessed with the validation set, followed by assessing the equivalence of observed and predicted EQ-5D scores on the full dataset controlling for sociodemographic factors. RESULTS: Different sets of PDQ-39 domains were associated with each EQ-5D domain. For example, PDQ-39 "Activities of Daily Living" and "Social Support" were associated with EQ-5D "Personal Care," while PDQ-39 "Emotional Well-being" was associated with EQ-5D "Anxiety/Depression." Over one-third (37.5 %) of predictions from ordinal regressions had an error <0.01 % (compared to 6.3 % for linear regressions). The EQ-5D scores predicted with ordinal regression using PDQ-39 domains were similar in distribution and association with sociodemographic factors to the observed EQ-5D scores. CONCLUSIONS: Of the four methods tested, using PDQ-39 domains in ordinal regression was superior for mapping EQ-5D scores. The function reported here may prove particularly useful for cost-utility analyses comparing Parkinson's disease with other conditions.
Authors: R S Bucks; K E Cruise; T C Skinner; A M Loftus; R A Barker; M G Thomas Journal: Int J Geriatr Psychiatry Date: 2010-07-13 Impact factor: 3.485
Authors: Anette Schrag; Felix Geser; Michaela Stampfer-Kountchev; Klaus Seppi; Martin Sawires; Martin Köllensperger; Christoph Scherfler; Niall Quinn; Maria T Pellecchia; Paolo Barone; Francesca Del Sorbo; Alberto Albanese; Karen Ostergaard; Erik Dupont; Adriana Cardozo; Eduardo Tolosa; Christer F Nilsson; Håkan Widner; Olle Lindvall; Nir Giladi; Tanya Gurevich; Christine Daniels; Günther Deuschl; Miguel Coelho; Cristina Sampaio; Michael Abele; Thomas Klockgether; Nicole Schimke; Karla M Eggert; Wolfgang Oertel; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2006-06 Impact factor: 10.338
Authors: Yaroslav Winter; Sonja von Campenhausen; Julia Gasser; Klaus Seppi; Jens-P Reese; Karl-P Pfeiffer; Kai Bötzel; Wolfgang H Oertel; Richard Dodel; Werner Poewe Journal: J Neurol Date: 2009-11-28 Impact factor: 4.849
Authors: Gang Chen; Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Borja Del Pozo-Cruz; José C Adsuar; José Manuel Cordero-Ferrera; José María Abellán-Perpiñán; Fernando Ignacio Sánchez-Martínez Journal: Patient Date: 2018-12 Impact factor: 3.883
Authors: Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981
Authors: Jasmine Peak; Ilias Goranitis; Ed Day; Alex Copello; Nick Freemantle; Emma Frew Journal: Health Qual Life Outcomes Date: 2018-05-30 Impact factor: 3.186
Authors: Aline Schönenberg; Hannah M Zipprich; Ulrike Teschner; Julian Grosskreutz; Otto W Witte; Tino Prell Journal: Health Qual Life Outcomes Date: 2021-03-25 Impact factor: 3.186
Authors: Emily Fletcher; Victoria A Goodwin; Suzanne H Richards; John L Campbell; Rod S Taylor Journal: BMC Health Serv Res Date: 2012-11-23 Impact factor: 2.655